GEN vs. DOCU, PATH, PCOR, ESTC, CFLT, DUOL, SPSC, BRZE, SQ, and PLTR
Should you be buying Genesis Healthcare stock or one of its competitors? The main competitors of Genesis Healthcare include DocuSign (DOCU), UiPath (PATH), Procore Technologies (PCOR), Elastic (ESTC), Confluent (CFLT), Duolingo (DUOL), SPS Commerce (SPSC), Braze (BRZE), Block (SQ), and Palantir Technologies (PLTR). These companies are all part of the "prepackaged software" industry.
Genesis Healthcare (NYSE:GEN) and DocuSign (NASDAQ:DOCU) are both large-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.
Genesis Healthcare has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, DocuSign has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
Genesis Healthcare has a net margin of 17.83% compared to DocuSign's net margin of 2.68%. Genesis Healthcare's return on equity of 155.48% beat DocuSign's return on equity.
In the previous week, DocuSign had 4 more articles in the media than Genesis Healthcare. MarketBeat recorded 12 mentions for DocuSign and 8 mentions for Genesis Healthcare. DocuSign's average media sentiment score of 0.77 beat Genesis Healthcare's score of 0.00 indicating that DocuSign is being referred to more favorably in the news media.
82.1% of Genesis Healthcare shares are held by institutional investors. Comparatively, 77.6% of DocuSign shares are held by institutional investors. 3.3% of Genesis Healthcare shares are held by company insiders. Comparatively, 17.8% of DocuSign shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Genesis Healthcare received 55 more outperform votes than DocuSign when rated by MarketBeat users. Likewise, 65.68% of users gave Genesis Healthcare an outperform vote while only 59.71% of users gave DocuSign an outperform vote.
Genesis Healthcare has higher revenue and earnings than DocuSign. Genesis Healthcare is trading at a lower price-to-earnings ratio than DocuSign, indicating that it is currently the more affordable of the two stocks.
Genesis Healthcare currently has a consensus price target of $26.00, indicating a potential upside of 26.03%. DocuSign has a consensus price target of $60.25, indicating a potential upside of 5.33%. Given Genesis Healthcare's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genesis Healthcare is more favorable than DocuSign.
Summary
Genesis Healthcare beats DocuSign on 13 of the 18 factors compared between the two stocks.
Get Genesis Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genesis Healthcare Competitors List
Related Companies and Tools
